Xtl Biopharmaceuticals (XTLB) Other Non-Current Liabilities (2021 - 2022)
Xtl Biopharmaceuticals (XTLB) posted quarterly Other Non-Current Liabilities of $22000.0 for Q2 2022, down 97.91% on a QoQ basis from $1.1 million in Q4 2021.
Xtl Biopharmaceuticals (XTLB) Other Non-Current Liabilities (2021 - 2022) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Other Non-Current Liabilities for 2 consecutive years, with $22000.0 the latest figure, recorded in Q2 2022.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $22000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $22000.0 (changed N/A YoY) and the FY2021 annual result came in at $1.1 million, changed N/A from the prior year.
- Other Non-Current Liabilities slipped to $22000.0 in Q2 2022 per XTLB's latest filing, from $1.1 million in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for XTLB reached as high as $1.1 million in Q4 2021 and fell as low as $22000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 22,000.00 |
| Dec 31, 2021 | 1.05 Mn |